Effectiveness of the 2023–2024 Omicron XBB.1.5 COVID-19 Vaccine
Author Information
Author(s): Kopel Hagit, Araujo Andre B, Bogdanov Alina, Zeng Ni, Winer Isabelle, Winer-Jones Jessamine P, Lu Tianyi, Marks Morgan A, Bonafede Machaon, Nguyen Van Hung, Martin David, Mansi James A
Primary Institution: Moderna, Inc.
Hypothesis
This study aimed to evaluate the vaccine effectiveness of mRNA-1273.815 in preventing COVID-19-related hospitalizations and medical encounters among adults.
Conclusion
The mRNA-1273.815 vaccine provides significant protection against COVID-19-related hospitalizations and medically attended COVID-19 in adults.
Supporting Evidence
- Vaccine effectiveness was 60.2% against COVID-19-related hospitalizations.
- Vaccine effectiveness was 33.1% against medically attended COVID-19.
- Results were consistent across subpopulations including older adults and those with underlying conditions.
Takeaway
The new COVID-19 vaccine helps keep people from getting really sick and needing to go to the hospital.
Methodology
A retrospective cohort study using linked electronic health record and claims data to compare vaccinated and unvaccinated adults.
Potential Biases
Potential residual confounding may exist due to unmeasured characteristics.
Limitations
The study may not be generalizable to uninsured individuals and is subject to selection bias due to its nonrandomized nature.
Participant Demographics
Mean age was 63 years; 57% were female, and over 60% had underlying medical conditions.
Statistical Information
P-Value
0.0001
Confidence Interval
95% CI: 53.4–66.0 for hospitalizations; 30.2–35.9 for medically attended COVID-19
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website